Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Scripps Research Institute Study Points to Potential New Therapies for Cancer and Other Diseases

Researchers at The Scripps Research Institute (TRSI) are fueling the future of cancer treatment by improving a powerful tool in disease defense: the body’s immune system. By revealing a novel but widespread cell signaling process, the scientists may have found a way to manipulate an important component of the immune system into more effectively fighting disease.

The study, recently published online ahead of print by the journal Blood, shows that disabling a particular enzyme, called ItpkB, in mice improves the function of a type of immune cell called Natural Killer cells.

“This is an exciting finding because it could possibly lead to the development of drugs that improve Natural Killer cell function,” said TSRI Associate Professor Karsten Sauer, PhD, who led the study. "Natural Killer cells have gained clinical interest as innovative biological therapeutics for certain cancers and also in certain infectious diseases.”

The Body’s ‘SWAT Team’

Natural Killer cells patrol the body and detect characteristic alterations on the surface of cancer cells or virus-infected cells. Through a complicated and little understood signaling machinery—a domino effect of molecular reactions in a cell that ultimately produces a certain signal—Natural Killer cells then destroy such ”stressed” cells.

Compared to other types of immune cells, Natural Killer cells kill these cells quickly. This makes Natural Killer cells important early responders of the immune system. Not surprisingly, researchers have explored engaging this "SWAT team" of the body therapeutically, particularly in blood cancers.

However, to date, the therapeutic efficacy of Natural Killer cells has been limited. “A key bottleneck is our limited understanding of signaling mechanisms that dampen Natural Killer cell function,” Sauer said.

Sauer and colleagues’ new research reveals crucial details of this puzzle.

A Way to Prime the Attack

The Sauer group had previously identified ItpkB as a key regulator of immune function. ItpkB acts primarily by producing IP4, a small molecule messenger that controls the functions of various other important signaling molecules. IP4 can improve or inhibit signaling depending on the cell type in which it is produced.
The new research showed that Natural Killer cells from mice lacking ItpkB show elevated signaling and function better than Natural Killer cells that have the enzyme. As a result, mice lacking ItpkB are more effective than mice expressing ItpkB in attacking cells that display characteristic surface changes of cancer cells.

“The enzyme ItpkB has unique features that facilitate its highly specific inhibition by small molecules,” said Sauer. "Our findings suggest that such compounds could possibly be used to improve Natural Killer cell function therapeutically. If successful, this could overcome a bottleneck and engage the body's SWAT team to fight cancer."

In addition to Sauer, Eugene Park of Washington University School of Medicine was a co-first author of the study, "Inositol Tetrakisphosphate Limits NK Cell Effector Functions by Controlling Phosphoinositide 3-Kinase Signaling.” Other authors include Sabine Siegemund, Luise Sternberg and Stephanie Rigaud of TSRI and Anthony R. French, Joseph A. Wahle, A. Helena Jonsson, Wayne M. Yokoyama and co-corresponding author Yina H. Huang of Washington University School of Medicine. For more information, see

The research was supported by grants from the National Institutes of Health (AI070845, GM088647, AI089805 and AI007606), The Leukemia and Lymphoma Society Scholar Award 1440-11 and Deutsche Forschungsgemeinschaft fellowship SI 1547/1-1.

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, TSRI has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see
For information:
Office of Communications
Tel: 858-784-8134
Fax: 858-784-8136

Mika Ono | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Fatty liver disease and scarring have strong genetic component
02.10.2015 | University of California - San Diego

nachricht What is the cost of lung cancer in Germany?
01.10.2015 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New Sinumerik features improve productivity and precision

EMO 2015, Hall 3, Booth E06/F03

  • Drive optimization called automatically by the part program boosts productivity
  • Automatically switching the dynamic values to rapid traverse and interpolation...

Im Focus: LZH presents additive manufacturing at the LABVOLUTION

The Laser Zentrum Hannover e.V. (LZH) will present how laser-based technologies can contribute to the laboratory of the future at the LABVOLUTION in Hannover in Hall 9, Stand E67/09, from October 6th to 8th, 2015. As a part of the model lab smartLAB, the LZH is showing how additive manufacturing, better known as 3-D printing, can make experimental setups more flexible.

Twelve partners from science and industry are presenting an intelligent and innovative model lab at the special display smartLAB. A part of this intelligent...

Im Focus: New polymer creates safer fuels

Before embarking on a transcontinental journey, jet airplanes fill up with tens of thousands of gallons of fuel. In the event of a crash, such large quantities of fuel increase the severity of an explosion upon impact.

Researchers at Caltech and JPL have discovered a polymeric fuel additive that can reduce the intensity of postimpact explosions that occur during accidents and...

Im Focus: 3-D printing techniques help surgeons carve new ears

When surgical residents need to practice a complicated procedure to fashion a new ear for children without one, they typically get a bar of soap, carrot or an apple.

To treat children with a missing or under-developed ear, experienced surgeons harvest pieces of rib cartilage from the child and carve them into the framework...

Im Focus: Walk the line

NASA studies physical performance after spaceflight

Walking an obstacle course on Earth is relatively easy. Walking an obstacle course on Earth after being in space for six months is not quite as simple. The...

All Focus news of the innovation-report >>>



Event News

EHFG 2015: Securing healthcare and sustainably strengthening healthcare systems

01.10.2015 | Event News

Conference in Brussels: Tracking and Tracing the Smallest Marine Life Forms

30.09.2015 | Event News

World Alzheimer`s Day – Professor Willnow: Clearer Insights into the Development of the Disease

17.09.2015 | Event News

Latest News

Infrared thermography can detect joint inflammation and help improving work ergonomics

02.10.2015 | Medical Engineering

Semiconductor nanoparticles show high luminescence in a polymer matrix

02.10.2015 | Materials Sciences

New Sinumerik features improve productivity and precision

02.10.2015 | Trade Fair News

More VideoLinks >>>